#Types Of Neuroendocrine Tumours
Link
It is unknown what specifically causes neuroendocrine tumours. These malignancies start in neuroendocrine cells, which resemble neuron and hormone-producing cells in their characteristics. Your body is full of neuroendocrine cells.
When neuroendocrine cells experience DNA changes (mutations), neuroendocrine tumours form, and a cell’s DNA carries information on what to do. The adjustments instruct the neuroendocrine cells to increase quickly and develop into a tumour.
#symptoms of neuroendocrine tumours#Neuroendocrine Tumors#Types Of Neuroendocrine Tumours#Lung#Pancreas#Gastrointestinal (GI) tract#Causes Of Neuroendocrine Tumours#Risk factors for neuroendocrine tumours
1 note
·
View note
Text
Trusted Oncological Care With Trusted Hands
It is but natural that the best cancer hospital in Delhi is the right place to find the best oncologist in Delhi. Equipped with the highest qualifications and ably assisted by an efficient support staff, the oncologists at the world-class Indraprastha Apollo Hospital provide cancer patients the best care possible. The top-end facilities, equipment and techniques available to a cancer specialist here go a long way in strongly backing the healing process of every patient.
Besides qualifications and experience, empathy and compassion are equally important qualities to look for in the best oncologist in Delhi. At the Indraprastha Apollo Hospital, each member of the Apollo Cancer Institute is committed to providing cancer patients with every life-saving treatment available. For example, Image Guided Radiotherapy (IGRT), Stereotactic Body Radiotherapy (SBRT), Frameless Stereotactic Radiosurgery (SRS), 3D Conformal Radiotherapy, Intensity Modulated Radiotherapy (IMRT), and High Dose Rate (HDR) Brachytherapy are offered here for early detection of cancer and advanced surgical technology known as da Vinci robotical surgical system help cancer surgeons perform complicated surgeries with ease ensuring best outcome. In addition, the Tumour Board and Group Tumour Board meetings foster discussions between surgical, medical and radiation oncologists as do the Cancer Awareness Programs and counselling sessions offered at the Apollo Cancer Institute.
Follow-up constitutes an important component of treatment and is an integral part of the management protocols carried out by the Apollo Cancer Institute. Early detection and timely management of recurrence is the principle objective of follow-up in cancer management. The best oncologist in Delhi firmly believes this not only enhances survival but improves quality of life of patients.
Take a look at some of the top cancer specialists at Indraprastha Apollo Institute, who would each qualify to be the best oncologist in Delhi:
Dr Anil D’Cruz
MBBS, MS, DNB, FRCS (HON.
With over three decades of experience, Dr D’Cruz is a renowned surgical oncologist focusing primarily on head and neck cancers. His major areas are management of neck metastasis, conservative laryngeal surgery, cancers of the oral cavity, thyroid, quality of life issues and global health.
Dr Manish Singhal
MBBS, MD, DM(AIIMS)ECMO
Dr Singhal’s career spans over twenty years, largely covering all types of chemotherapy, intensive protocols, immunotherapy, hormonal therapy in addition to dealing with oncological emergencies, including medical care of patients.
Dr Dipanjan Panda
MBBS, MD, DM
One of the best medical oncologists in Delhi, Dr Panda’s area of expertise lies in gastrointestinal and hepatic pancreatico biliary malignancy, breast and gynaecological malignancy, lung and head neck cancer, genito-urinary malignancy, lymphoma and myeloma (haematological malignancy) and rare tumours like neuroendocrine tumours.
Dr Shuaib Zaidi
MBBS, MS (SURGERY), DNB (SURGERY), MCH (SURGICAL ONCOLOGY)
The Academic Coordinator and Senior Consultant in the Department of Surgical Oncology, Dr Zaidi has over twenty years of experience as a surgical oncologist. He specialises in the treatment of thoractic cancer, gastrointestinal cancer, PIPAC (Pressurised Intraperitoneal Chemotherapy), breast cancer and complex gynaecologic oncology.
Dr Praveen Garg
MBBS, M.S.(GEN.SURGERY), M.CH.(ONCOSURGERY)
Dr Garg specialises in the diagnosis, treatment and surgical management of malignant conditions in various parts of the body, and has advanced training in parathyroid and thyroid cancer surgeries, breast conservation surgeries, mastectomies and breast tissue reconstructions.
Dr Ruqaya Ahmed Mir
MBBS, DNB
Trained in robotic surgery, Dr Mir routinely performs major oncological resectional surgical procedures for head and neck cancers, lung and oesophageal cancers, major gastrointestinal malignancies, breast and gynaecological malignancies and soft tissue sarcomas.
To get in touch with the best oncologist in Delhi, contact Indraprastha Apollo Hospital
2 notes
·
View notes
Text
Today Star’s Prompt Led to NBC’s Antonia Hylton’s Cancer Diagnosis
Antonia Hylton, an NBC News correspondent, recently announced her struggle with a rare kind of cancer known as neuroendocrine tumor. She said how she originally ignored her symptoms, attributing them to her hectic lifestyle. However, after learning of Craig Melvin's brother's death from colon cancer and watching a TikTok video about a young woman with colon cancer, Antonia decided to see a doctor.
On her 30th birthday, she received the devastating news that she had a polyp, which turned out to be a neuroendocrine tumour. Despite her initial concern, Antonia was glad to find that the condition was detected early and treatable. After a series of procedures and examinations, her most recent scan revealed that she is fully cancer-free. This event taught her the value of listening to her body and valuing her health. While Antonia enjoys her job at NBC, she now understands the importance of putting herself first and not ignoring any potential health risks.
On November 30, Antonia Hylton appeared on Today's Third Hour, where she revealed for the first time her cancer diagnosis.
The NBC News writer talked to hosts Craig Melvin, Al Roker, Sheinelle Jones, and Dylan Dreyer about her battle with a neuroendocrine tumor, a rare type of cancer.
Antonia informed the anchors she had been ignoring her symptoms, which included recurrent stomach problems, for quite some time.
She confessed that it was "easy for me to just write it off" at first, blaming the troubles on her hectic travel schedule.
0 notes
Link
0 notes
Text
Understanding Pancreatic Tumours: Their Types, Risks, and Treatment Approaches From The Best Pancreatic Surgeon In Surat
Pancreatic tumours are a complex and often challenging medical condition that affects thousands of individuals each year. These tumours can vary in type, present significant risks, and require careful consideration when determining the most effective treatment approach. In this blog, Dr Dhaval Mangukiya, one of the best laparoscopic surgeons, delves into the different types of pancreatic tumours, the associated risks, and the various treatment options available to patients.
Types of Pancreatic Tumours
Pancreatic tumours vary in terms of their symptoms and prognosis. Some of them are:
Pancreatic Adenocarcinoma
The best pancreatic surgeons in Surat, including Dr Dhaval Mangukiya, say that this type of tumour is the most common form of pancreatic cancer and accounts for the majority of cases. Pancreatic adenocarcinoma typically originates in the cells lining the pancreatic ducts and is known for its aggressive nature and tendency to metastasize.
Pancreatic Neuroendocrine Tumours (PNETs)
PNETs are less common than pancreatic adenocarcinoma but can still pose significant health risks. These tumours develop from hormone-producing cells in the pancreas called neuroendocrine cells. PNETs can be either functional, meaning they produce hormones, or non-functional, meaning they do not produce hormones.
Cystic Tumours
Cystic tumours of the pancreas are fluid-filled growths that can be benign or malignant. These tumours often present as cystic lesions on imaging studies and may require further evaluation to determine their nature and appropriate management.
Risks Associated with Pancreatic Tumours
1. Age: Advanced age is a significant risk factor for developing pancreatic tumours, with the majority of cases diagnosed in individuals over the age of 65.
2. Smoking: Cigarette smoking is strongly associated with an increased risk of pancreatic cancer. Smokers are at a higher risk of developing pancreatic tumours compared to non-smokers.
3. Family History: As per the experience of Dr Dhaval Mangukiya, one of the best pancreatic surgeons in Surat, individuals with a family history of pancreatic cancer or certain genetic syndromes, such as hereditary pancreatitis or Lynch syndrome, have an elevated risk of developing pancreatic tumours.
4. Chronic Pancreatitis: Chronic inflammation of the pancreas, known as chronic pancreatitis, is a risk factor for the development of pancreatic cancer over time.
5. Obesity and Diet: Obesity, a diet high in red and processed meats, and low fruit and vegetable intake are linked to an increased risk of pancreatic tumours.
Treatment Approaches for Pancreatic Tumours
Surgery
Surgical resection is often considered the primary treatment for operable pancreatic tumours. Depending on the location and stage of the tumour, procedures such as Whipple surgery (pancreaticoduodenectomy), distal pancreatectomy, or total pancreatectomy may be performed to remove the tumour and affected pancreatic tissue, says Dr. Dhaval Mangukiya, one of the best laparoscopic surgeon in Surat.
Chemotherapy
Chemotherapy may be used as neoadjuvant therapy before surgery to shrink the tumour or as adjuvant therapy after surgery to reduce the risk of recurrence. Chemotherapy regimens commonly used for pancreatic cancer include gemcitabine, nab-paclitaxel, FOLFIRINOX, and 5-fluorouracil (5-FU) based combinations.
Radiation Therapy
Radiation therapy may be utilized alone or in combination with chemotherapy to treat pancreatic tumours. This treatment modality uses high-energy beams to target and destroy cancer cells while minimizing damage to surrounding healthy tissue.
Targeted Therapy
Targeted therapy drugs are designed to specifically target cancer cells based on their molecular characteristics. Examples of targeted therapies used for pancreatic cancer include erlotinib, cetuximab, and bevacizumab.
Immunotherapy
Immunotherapy drugs work by stimulating the body’s immune system to recognize and attack cancer cells. While immunotherapy has shown promise in other types of cancer, its efficacy in pancreatic cancer is still being studied in clinical trials.
Palliative Care
For advanced pancreatic cancer that cannot be cured, palliative care focuses on relieving symptoms, improving quality of life, and providing emotional support for patients and their families.
Final Thoughts
Pancreatic tumours encompass a diverse range of malignancies with varying types, risks, and treatment approaches. Early detection and prompt intervention are crucial for improving outcomes and enhancing the quality of life for individuals diagnosed with pancreatic tumours. The best gastrointestinal surgeons in Surat have shared the symptoms and treatment options to create awareness about the types of pancreatic tumours, recognizing associated risk factors, and exploring available treatment options. Patients and healthcare providers can work together to develop personalized treatment plans tailored to individual needs and circumstances.
0 notes
Text
Everolimus (Afinitor) for pancreatic neuroendocrine tumours
The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others it may control the cancer and its symptoms. Your doctor will explain to you whether you will receive chemotherapy or another type of treatment, or a combination of both. Your doctor or nurse will be happy to answer any questions you have about your treatment. You will find it useful to refer to the booklet ‘Chemotherapy, a guide’ which gives general information on chemotherapy and side effects.
0 notes
Text
What is the Initial Phase of Esophageal Cancer?
Early stages of stomach cancer are typically devoid of symptoms. Therefore, it is sometimes not diagnosed until a later stage.
The stage of your cancer is used to determine the optimal treatment option. The stage indicates how far the stomach cancer has progressed to other places in your body.
Stage 0 of stomach cancer is the earliest known as "carcinoma in situ." This indicates that the malignancy is limited to the surface of the stomach lining. Cancer has not moved beyond the stomach or to any lymph nodes, and the treatment is quite effective.
Adenocarcinoma is a form of stomach cancer that originates in the stomach lining. It begins in epithelial cells in the mucosa layer of the stomach and, as it spreads, invades the muscularis and serosa layers of the stomach wall.
Other kinds of stomach cancer are lymphoma (immune system), gastrointestinal stromal tumours (GIST), and neuroendocrine carcinomas. 4% of all stomach cancers are caused by lymphoma.
It is uncommon for this type of cancer to originate in the stomach lining, but it might arise from the lymphatic tissue that drains fluid and fights infections. In some instances, lymphoma may spread to other organs.
It might be challenging to diagnose and treat this type of cancer. Your healthcare team will collaborate with you to establish the optimal treatment plan for your requirements.
Chemotherapy employs drugs that circulate throughout the body and destroy cancer cells. It can be administered intravenously, orally, or in conjunction with radiation therapy (radiotherapy).
Surgical removal of a portion or all of the stomach and lymph nodes in the area is a popular alternative treatment. This is accomplished by inserting an endoscope, a flexible tube, down your neck while asleep.
Additionally, surgery can be done to remove aberrant cells from the stomach lining that cannot be removed via biopsy. This is sometimes referred to as high-grade dysplasia (HGD), which can progress to invasive malignancy if surgery is not performed.
The initial stage of stomach cancer begins at the junction of the oesophagus and the long tube that delivers food from the mouth to the stomach. It is known as the gastroesophageal junction, and a doctor can examine it using an endoscope, a small tube that passes down the throat.
Cancer begins in the cells of the mucosa, which is the deepest layer of the stomach. This is also where it grows into the stomach's muscle and connective tissue, or serosa.
It is also where cancer spreads to surrounding lymph nodes (N) and potentially to other body regions. These are termed metastatic diseases, and they are tough to treat.
However, some therapies can alleviate symptoms and offer you some control over your life. This typically includes surgery to remove a portion or the entirety of the stomach, chemotherapy, and radiation therapy.
These treatments can cure cancer and improve your health. They can also reduce the likelihood that cancer will return.
The outcome of treatment for Stage I cancer depends on the patient's health and cancer's spread. Your doctor will chat with you about what's best for you.
If the disease has not gone to the lungs or other areas of the body, chemotherapy and radiation therapy may be used as primary treatments. If cancer has progressed to these locations, you may be unable or unwilling to undergo surgery.
You will undergo a blood test, an upper endoscopy, and more tests to screen for cancer symptoms. These tests can assist in determining whether the stomach cancer begins in the mucosa, muscularis mucosa, or serosa.
Your physician will then describe the "stage" of your stomach cancer. The stage describes how far cancer has gone and how deadly it is. In addition, it enables doctors and patients to collaborate on a treatment plan tailored to their needs.
0 notes
Text
Get all your questions answered about Gastrointestinal cancer
What are the most common types of gastrointestinal cancer?
Gastrointestinal cancers are the most common cancers worldwide. As a whole they are responsible for more cancers and deaths from cancer than any other system in the body. One in every twenty people will be affected by colon cancer, one of the GI cancers.
Gastrointestinal cancer (GI) affects the organs of your digestive tract. The most common GI cancers include the following:
Anal cancer, colon cancer, and rectal cancer
Esophageal cancer
Gallbladder cancer
Liver cancer
Pancreatic cancer
Small intestinal cancer
Stomach cancer (gastric cancer)
The most common cancer types are:
Adenocarcinoma
Squamous cell carcinoma
Neuroendocrine tumours
Gastrointestinal stromal tumours (GISTs)
What are the most common symptoms of GI cancer?
You may have no symptoms in the early stages of GI cancer. When Gastrointestinal cancer cast symptoms they have usually grown sufficiently big.They are usually diagnosed at this point when they start causing symptoms.
When gastrointestinal cancer is advanced enough to cause symptoms, they may include:
Cramping or pain in the abdomen
Stool that is bloody or black colored
Changes in bowel habits especially recent change such as diarrhoea or constipation, or changes in stool consistency or narrowing
Swallowing Difficulties
Digestive issues
Jaundice (yellowing of the eyes and skin)
Vomiting and nausea
The abdomen is swollen
Tiredness, weakness, weight loss, or appetite loss
What are the causes of developing GI cancer?
GI tract cancers develop when the cells lining one or more of the digestive tract's organs begins to grow uncontrolled, producing tumours and occasionally spreading to lymph nodes and other organs.
The cause of GI cancer is still not fully known to medical experts. Still, cell damage increases the likelihood of abnormalities appearing, which can be caused by infections, obesity, smoking, and some environmental risk factors. GI cancers can also be hereditary i.e. they run in family.
Risk factors that increase your chances of developing GI cancer are:
Infection with Hepatitis A or B (liver cancer)
Infection with Helicobacter Pylori (stomach cancer)
Smoking
Alcoholism
Gastritis
Obesity or being overweight
Having a history of GI cancer or another cancer
Previous surgery on one or more digestive organs
Family history of GI cancer
Polyps that had previously grown in the colon or stomach
How can I lower my chances of developing gastrointestinal cancer?
It has been observed that more than 2/3 of GI cancers are lifestyle related. Several lifestyle changes can lower your chances of developing these cancers. These include avoiding alcohol and smoking, eating plenty of green vegetables, avoiding preserved or burnt meats, maintaining a healthy weight, and exercising on a regular basis.
What are my chances of a cure if any of these occur?
When detected early these cancers can be cured. Even in advanced stages with a combination of surgery, chemotherapy and radiotherapy one can think of cure. But needless to say do not ignore any early symptoms.
Will my gallbladder stones cause cancer?
Although gallstones are common, only a small percentage of those who have them will develop gallbladder cancer. Your cancer risk increases if a gallstone causes pain, is large, or you have a close relative who has gallbladder cancer.
Can these cancers be treated with Robotic/Laparoscopic surgery?
The robotic/laparoscopic technique has completely transformed the field of surgery.
In addition to the obvious cosmetic benefits, research has shown that it results in:
Less surgical trauma
A shorter hospital stay
Less blood loss
A lower complication rate
An earlier return to work
Laparoscopic surgery is increasingly being used to treat colorectal, esophageal, and gastric cancers. Thanks to technological advances and increasing surgeon expertise, cancers of the liver, pancreas, and gallbladder can now be operated on laparoscopically in selected cases.
If you are experiencing unusual GI symptoms or want to learn more about the disease, get an appointment with Dr. Neeraj Goel, an expert GI Surgeon in Delhi. He is always there to assist you at every stage of gastrointestinal cancer.
TAG- Gastrointestinal Cancer surgery in Delhi, Gastrointestinal Cancer Doctor in Delhi
0 notes
Text
What is Dota Pet Scan and its Procedure Guidelines
PET (positron emission tomography) uses a combination of transmitted and emitted X-rays to scan different parts of the body to detect disease in organs such as the lungs, liver, pancreas kidneys, bladder, stomach, intestines, ovaries, etc. DOTA-PET/CT uses a different radiotracer that is more specific to neuroendocrine tumours.
DOTA- PET/CT [BJ1] scan is used to diagnose tumours, illnesses, injuries, and disorders, as well as to evaluate the functioning of tissues and abnormal cells in the body. It generates three-dimensional images of the body, making diagnosis and evaluation easy, quick, and accurate.
How is it different from other scans and what are its benefits?
A DOTA-PET/CT PET scan is a type of medical scan that employs the use of a radioactive tracer to detect disease or abnormalities in the body. Along with abnormal cell activity, it examines the body's internal structures.
A Dota PET/CT scan has many potential benefits, including high accuracy in diagnosing neuroendocrine disorders and detecting disease earlier than other imaging tests as well as for monitoring and follow-up. Also, small tumours that may not be visible on other imaging tests, can be detected on DOTA.
Process and Procedure Guidelines for DOTA-PET/CT Scan
The process of a DOTA- PET/CT scan can differ depending on the procedure being performed. This scan is a nuclear medicine examination that employs an imaging device to examine the function and structure of your organs and tissues.
The DOTA-PET/CT scan is not recommended for pregnant women or children and if the patient is a lactating mother, the doctor should be notified. Jewellery and accessories are not allowed during scanning and the patient should not consume anything for 3-4 hours before the examination.
The patient is injected with a small amount of radioactive DOTA tracer, which circulates through the body and is absorbed by the cells. Actively growing cells, such as neuroendocrine cancer cells, consume more DOTA than normal cells. The PET scanner detects areas with high cell activity and generates images of them.
The scan can take 1-2 hours to complete because the tracer must be distributed throughout the body. PET scans pose no harm. Because the amount of radiation exposure from a PET scan is low, there are no side effects. You can resume your normal activities following a PET scan. Reports are typically delivered within 24-48 hours.
If the scan is done before 12 noon, then the report is ready the same day if the scan is done before 12 noon. However, the report is available the next day. It is simple to evaluate neuroendocrine tumours at different phases of the disease using our 68-Ga labelled DOTATOC.
0 notes
Text
Today Star’s Prompt Led to NBC’s Antonia Hylton’s Cancer Diagnosis
Antonia Hylton, an NBC News journalist, recently discussed her struggle with a rare type of cancer, a neuroendocrine tumor, on the Third Hour of Today. She admits to neglecting her symptoms, particularly chronic stomach pains, for a long period, blaming them on her hectic travel schedule and nutrition.
However, after hearing Craig Melvin's story about his brother's death from colon cancer and watching a TikTok video about a young woman with colon cancer, Antonia decided to see a doctor. On her 30th birthday, she received a worrying phone call from her doctor after a colonoscopy discovered a polyp that turned out to be a rare neuroendocrine tumour. Fortunately, it was found early and treated.
0 notes
Text
What are the types of Gastrointestinal (GI) Cancer?
Gastrointestinal cancer is an array of cancers affecting the digestive system and the gastrointestinal tract. It is commonly a group of cancers that attack the digestive system starting from the colon, rectum, pancreas, stomach, liver, anus, small intestines, biliary system, gallbladder, and oesophagus.
Now that we know that gastrointestinal cancer can damage your digestive system let’s look at the types of gastrointestinal cancer and gastrointestinal cancer symptoms.
Types of Gastrointestinal Cancer
There are many types of gastrointestinal cancers that affect multiple body parts, and tumours can develop at any part and spread to other parts. Primary GI, called Metastatic gastrointestinal cancer, originates in the GI or digestive tract.
There are also other types of gastrointestinal cancer, these are:-
Oesophageal Cancer
Gastrointestinal Stromal Tumors
Gastric (stomach) Cancer
Colorectal Cancer
Anal Cancer
Pancreatic Cancer
Liver Cancer
Neuroendocrine Tumors
Bile Duct Cancer
Small Intestine Cancer
Rectal Cancer
Let’s look at the most common gastrointestinal cancer in detail:-
Oesophageal Cancer
Oesophageal cancer occurs in the oesophagus. The oesophagus is a tube or also referred to as a food pipe, and its function is to carry food and liquid from the throat to the stomach.
Oesophagal cancer is a type of gastrointestinal cancer that arises due to the development of cells on the layer of the oesophagus tube.
There are three types of oesophagal cancer:-
Adenocarcinoma - grows at the lower end of the oesophagus
Squamous cell carcinoma - grows at the upper end of the oesophagus
Small cell carcinoma - it is a rare type of oesophagal cancer that starts from neuroendocrine (hormone-producing) cells
Symptoms of oesophagal cancer can be a change in voice, heartburn, sudden weight loss, pain near the cheek or back, pain while swallowing and long-lasting cough.
Gastrointestinal Stromal Tumors
GIST, or gastrointestinal stromal tumour, is the type of sarcoma that occurs in the digestive tract and is most commonly found in the small intestine and stomach.
Symptoms of gastrointestinal stromal tumours include abdominal pain, nausea, vomiting, bloody stools, indigestion, appetite loss, and swelling in the abdomen.
Some common ways to diagnose GIST are a physical exam and diagnostic tests such as blood tests, imaging tests, endoscopy and biopsy.
It can be treated using surgery, targeted therapy, Ablation and embolization. Radiation therapy can be used to reduce pain as a palliative care process.
Colorectal Cancer
Colon cancer, or colorectal cancer, grows in the large intestine (large bowel). It occurs due to the growth of a polyp that forms on the inner walls of the colon or rectum, the polyps are benign, but some cells later become cancerous due to abnormal growth of cells because of a change in DNA.
Symptoms of colon cancer include blacky, dark and bloody stools, changes in the look of the stool, long-lasting bloating, regular abdominal pain, and sudden weight loss.
Colon cancer can be diagnosed using colonoscopy and stool-based tests.
Pancreatic Cancer
Pancreatic cancer, or ductal carcinoma is one of the most common and growing cancers across the world; that occurs when cells in the pancreas start growing abnormally.
Symptoms of pancreatic cancer are increased blood sugar, jaundice, abdominal pain, appetite and weight loss.
There are two types of pancreatic cancer pancreatic exocrine cancer or Adenocarcinoma and pancreatic endocrine cancer or Islet cell cancer.
Liver Cancer
The growth of abnormal cells inside the liver causes liver cancer, and the liver is where primary cancer, like hepatocellular carcinoma, starts.
Liver cancer symptoms include jaundice, bloating, sudden weight loss, appetite loss, bloating and stomach pains.
Secondary and Primary Liver Cancer are the types of liver cancer
Hepatocellular carcinoma or Primary liver cancer - Occurs when cells grow within
Secondary liver cancer - metastatic cancer spreads to the liver from other body parts.
Conclusion
Gastrointestinal Cancer is a challenge to public health as the cases of this are increasing across the globe due to lifestyle changes. Chances of GI cancers can be avoided by improving the lifestyle, eating healthy and reducing consumption of alcohol and smoking.
1 note
·
View note
Text
What You Should Know About Nose Cancer
Nose cancer and sinuses accounts for less than 1% of the tumours. But the nose and the sinus give rise to a greater variety of tumours than any other site in the body. Infact, there are many types of tumours that can arise in the nose and sinuses. The most common are, squamous cell carcinoma, adenoid cystic carcinoma, adenocarcinoma, and Sino nasal undifferentiated carcinoma.
Other nose and sinus cancers include neuroendocrine carcinoma, mucoepidermoid carcinoma, melanoma and all types of sarcomas. To learn more about nose cancer and sinus cancer, here are some of the things you should know.
Which Patients Are Typically Eligible For Minimally Invasive Surgery?
If you think of the head as a football, these tumours are right at the centre and getting to them can be quite challenging. Invasive surgery is performed through the nose with cameras that magnify and avoid the need of making facial cuts in most cases.
This is an ideal way for tumours in the midline such as nose and sinus cancers. Over the past years, this remedy has evolved to being able to treat more advanced tumours. However, invasive surgery is not right for everyone. Tumours that involve the skin need more traditional surgery.
WhatAre The Treatment Options For Nose Cancer?
Treatment usually involves surgery, radiation, and chemotherapy. However, successful treatment requires tailoring the approach for the patient and specific disease. Before doctors determine the most appropriate treatment for nose cancer, they will identify the cancer type at first.
For example, except for T1 mucosal carcinomas, people with nose cancer require radiation therapy and surgery. Surgery removes the tumour and helps drain any of the affected sinuses. The person receives high doses of radiation therapy. Some people will require this treatment for the lymph nodes around the neck if the cancer has spread. Chemotherapy may also be prescribed.
Final Thoughts
Although it’s a long way, this is still an aggressive disease with little margin of errors. Given how this tumour really occurs, it is really important to deal with an experienced team of doctors. The team is very important because every component is equally vital to the overall success of your treatment. In case you note some few signs, it’s essential that you immediately pay visit to your doctor. From there, they will be in a position to give you a go-ahead.
0 notes
Text
Thyroid Cancer Drugs Market Worth Observing Strong Growth
Malignant cancer of the thyroid that develops from the par follicular and follicular thyroid cells is referred to as thyroid cancer. Thyroid nodules, which develop in the thyroid gland and can spread to other regions of the body, are another name for this type of cancer. About 90% of thyroid malignancies are benign. Some of the possible therapies include surgical thyroid gland excision, radiation ablation, and thyroid stimulating hormone (TSH) suppression medication.
One of the key factors propelling the expansion of the thyroid cancer drug market is the rise in neuroendocrine tumour cases among the global population. The expansion of the Thyroid Cancer Drugs Market is accelerated by increased investment in research and development activities to improve the overall course of diagnosis and treatment of thyroid cancer, as well as by expanding public knowledge of available treatments and technological improvement.
Read more @ https://creativeedge16.blogspot.com/2022/07/global-thyroid-cancer-drugs-market.html
#Thyroid Cancer Drugs#Thyroid Cancer Drugs Market#Thyroid Cancer Drugs Market Demand#Pharmaceutical#Coherent Market Insights
0 notes
Text
Elegant (3 + One + One) Carboannulation regarding Morita-Baylis-Hillman Carbonates using Pyridinium Ylides: Access to Spiro-gelatinpentadiene Oxindoles
Several tactics could ease #Link# the poisonous response. Polyelectrolyte layer-by-layer covering may hide your surfactant bilayer, as well as scientists may swap the particular surfactant together with chemically similar elements. Researchers may also switch the surfactant which has a biocompatible thiol or work with a polymerizable surfactant that could be "stitched" onto the nanorods reducing it's lability. In most these kind of situations, nevertheless, protein or another elements through the cellular media protect your manufactured top of the nanoparticles, which could drastically change the fees as well as practical groupings for the nanoparticle area.Target. Obvious arteriovenous fistula (AVF) is related to better analysis and quality of existence for sufferers in long-term dialysis. Whenever AVF problems can be alleged, MDCT is a superb non-invasive instrument pertaining to assessing your entire AVF framework and also deciding undoable circumstances for therapy. The objective of this article is show them the particular checking as well as meaning tactics and illustrate the conditions linked to first as well as past due fistula failures. CONCLUSION. MDCT can be a quickly, noninvasive, and accurate method of checking out AVF issues. Radiologists knowledgeable about these methods can help improve the analysis and excellence of existence regarding hemodialysis patients.Many of us current two studies in which many of us investigated no matter whether tactile focus will be modulated simply by motion preparing. Inside Test 1, contributors ready a saccade towards both the particular right of left forefinger, with respect to the message of an non-predictive hearing signal. In Test Two, individuals prepared to raise the actual right of left pointer finger as a result of the particular even stick. In half of the tests in findings, the suprathreshold vibratory stimulation had been assigned equal chance either to finger, this agreement the participants developed a speeded base response. The final results confirmed facilitation from the running of objectives provided with the goal #Link# place with the well prepared movement (Try things out 1), and also in the effector from the well prepared motion #Link# (Test Two). These types of answers are discussed inside composition regarding theories on motor preparation as well as spatial focus.Well-differentiated neuroendocrine tumours (netspreviously named "carcinoid tumours") are comparatively uncommon tumours via the actual diffuse neuroendocrine method; they are discovered generally inside the bronchial or stomach techniques. In Canada, gastroenterohepatic material symbolize less than 0.25% of oncology cases. As a result of family member rarity of those tumours, analytical as well as beneficial approaches change and therefore are frequently depending on personal medical doctor experience. Several Eu and also North American teams have developed comprehensive agreement guidelines for that prognosis and also treating well-differentiated gastroenterohepatic nets, along with 2006, Canadian consensus suggestions have been created by a new Canada specialist party. Your current and expanded latest Canadian guidelines depend on the opinion conference located in Paris, Italy, within '08 and so are depending on the most current literature.
1 note
·
View note
Text
Lupine publishers|Pineal Parenchymal Tumours
Pineal Parenchymal Tumours
Introduction
Pineal region tumours (PRT) are rare, accounting for less than 1% of all Central Nervous System (CNS) neoplasms1. Several distinct tumour types can occur in this location, reflecting the heterogeneity of the various structures of this small region. Pineal parenchymal tumours (PPT) represent approximately 27% of PRT and they are thought to be derived from pineocytes [1], cells with photosensory and neuroendocrine functions associated with melatonin production. According to the World Health Organization (WHO) 2016 classification of CNS tumours, PPT can be divided into three distinct tumour types, that differ in the degree of differentiation and biological behaviour: pineocytomas, pineal parenchymal tumours of intermediate differentiation (PPTID) and pineoblastomas [1].
The clinical presentation is similar across all types of PPT and usually arises from compression of adjacent structures, leading to obstructive hydrocephalus with increased intracranial pressure, neuro-ophtalmological dysfunction and brainstem or cerebellar dysfunction [2]. Age of presentation is variable, with most pineoblastomas occurring in children, whereas pineocytoma and PPTID being more common in adolescent and adult patients1. Treatment options vary according to the type and grade of PPT, and include surgical resection, radiotherapy and chemotherapy. A combination of these treatment modalities seems effective to improve survival in more aggressive cases [3]. Recent molecular research has been highlighting the heterogeneity in the molecular characteristics between these different histotypes. Although pineocytomas and PPTID have no reported syndromic associations or genetic susceptibilities, pineoblastomas have been described in patients with DICER1 [4] and RB1 [5,6] germline pathogenic variants. This review focuses in the current state of the art in PPT, highlighting how new molecular data can improve tumour classification and patient management.
Pineocytomas
Pineocytomas (WHO grade I) account for approximately 20% of all PPT [1]. They occur more frequently in adults (mean age of 43 years) and have a female preponderance [1]. On imaging, they present as well-defined masses localised in the pineal region [7]. They grow locally and are not associated with cerebrospinal fluid seeding or metastasis [8]. The reported 5-year survival rate is up to 100% in some series [8], and the extent of surgical resection is considered to be the major prognostic factor [9]. In the spectrum of PPT, pineocytomas have the highest degree of differentiation. They are composed of moderately cellular sheets of relatively small, uniform, mature cells, resembling normal pinealocytes, with frequent pineocytomatous rosettes. Immunohistochemical profile shows strong reactivity for synaptophysin, neuron-specific enolase and neurofilaments. Mitotic activity is low and Ki67 proliferation index is <1% [10]. Molecular studies on pineocytomas are restricted to cytogenetic studies in single case reports10,11. Numerical alterations involving chromosomes X, 5, 8, 11, 14, 19 and 22 and structural alterations of chromosomes 1, 3, 12 and 22 were described, but further studies are required to establish their association with tumorigenesis.
Pineal Parenchymal Tumours of Intermediate Differentiation
PPTID (WHO grades II or III) account for approximately 45% of all PPT [11]. They occur more frequently in adults (mean age of 41 years) and have a slight female preponderance [1]. On imaging, they present as large, poorly defined masses localised in the pineal region [12]. PPTID present features between pineocytomas and pineoblastoma, with a variable clinical and biological behaviour, from low grade tumours with delayed local recurrences to potentially aggressive neoplasms, with craniospinal dissemination, even after complete surgical resection [8,12].
Histologically, PPTID are moderately to highly cellular neoplasms, composed of diffuse sheets and/or large lobules of cells with mild to moderate atypia, a salt-and-pepper chromatin and distinct cytoplasm. Accordingly to their variable biological and clinical behaviour, mitotic activity, Ki-67 proliferation index, neuronal and neuroendocrine differentiation are also variable. Hence, similarly to pineocytomas, immunohistochemical profile show reactivity for synaptophysin, but variable labelling is seen for neurofilaments and chromogranin-A [1]. Reliable and reproductible grading criteria to define prognosis and treatment response have not been defined yet. Jouvet et al. proposed a grading system regarding mitotic activity and degree of neuronal differentiation. Grade II lesions were defined as having 0-5 mitoses per 10 highpower fields and significant immunostaining for neurofilaments. Grade III lesions were defined as PPT with either 6 or more than 6 mitoses or fewer than 6 mitoses but without immunostaining for neurofilaments [13]. More recently, Wu et al. demonstrated that immunoreactivity for CD24 and PRAME antibodies were significantly higher in PPTID grade III than in grade II, thus proposing the usefulness of these two novel markers for grading PPTID [14].
Recent molecular studies have shown that PPTID are distinct from other PPT in their genetic and transcriptomic characteristics. Using whole exome sequencing, Lee JC et al, described unique recurrent somatic small in-frame insertion (p.R313delinsPRR) in the KBTBD4 gene in PPTID, that were absent in other PPT [15]. Thereafter, Pfaff et al validated these results and further demonstrated PPTID as a distinct molecular subgroup according methylation profiling [6]. Additional molecular data regarding PPTID can be found in single case reports. Using a comprehensive NGS panel in two cases of grade III PPTID, Martinez et al. found inactivating ATRX mutations, a gene associated with protein loss and alternative lengthening of telomeres. Since this was the sole pathogenic genetic abnormality identified in this study they suggested that it may represent an important driver in these tumor subset in particular [16].
In a single case study, using targeted exome sequencing, mutations in genes encoding tuberous sclerosis 1 within the hamartin region of the protein and an additional mutation in IKAROS family zinc finger 3 were found. This type of mutation in tuberous sclerosis 1 have been correlated with clinical sensitivity to mammalian target of rapamycin inhibitors, which makes it an interesting candidate for personalized target therapy in these patients [17]. According to cytogenetic studies, the most common chromosomal imbalances found in PPTID are 4q gain, 12q gain and 22 loss [18]. Additionally, Böhrnsen et al. highlighted the gains of 16p in one case of grade II PPTID [19].
Pineoblastomas
Pineoblastomas (WHO grade IV) account for approximately 35% of all PPT [1]. They occur more frequently in children (first two decades of life; mean age of 18 years) and have a slight female preponderance [1]. On imaging, they present as large, multilobulated masses in the pineal region, with frequent invasion of surrounding structures (including the leptomeninges, third ventricle, and tectal plate) [20]. Their locally invasive nature, tendency to disseminate along cerebrospinal fluid pathways and the occasional occurrence of extra-cranial metastasis, brings them to be the most aggressive type of PPT [21]. Prognosis seems to be most affected by the presence of disseminated disease at the time of diagnosis, patient age and extent of surgical resection [1].
In the spectrum of PPTs, pineoblastomas have the lowest degree of differentiation. They are composed of highly cellular patternless sheets of densely packed small cells, resembling other so-called small blue round cell or primitive neuro-ectodermal tumours of the CNS. Tumour cells have a high nuclear-to-cytoplasmic ratio, indistinct cell borders, hyperchromatic nuclei with irregular shapes and occasional small nucleoli, and scant cytoplasm. There are no pineocytomatous rosettes, but occasional Homer-Wright and Flexner-Wintersteiner rosettes may be seen. Necrosis is a common feature, and mitotic activity / Ki-67 proliferation index are generally high. Immunohistochemical profile shows variable positivity for synaptophysin, neuron-specific enolase, neurofilaments and chromogranin-A [1]. Recently, important molecular studies have been showing heterogeneity in the molecular characteristics in pineoblastomas. Concerning cytogenetics, Böhrnsen et al. found that pineoblastomas show frequent gains at 7, 9q, 12q, 16p, 17 and 22q, highlighting gain of 16p as a common alteration in PPT in general [19].
In a recent international collaboration study6, 107 cases of pineoblastoma were characterized by genome-wide DNA methylation profiling, gene panel sequencing and miRNA sequencing. Methylation analysis defined five subtypes of pineoblastoma, with important clinical and genomic heterogeneity. The RB subtype displayed similarities with retinoblastoma, and included cases associated with trilateral retinoblastoma; it occurred in a younger age and was characterised by somatic or germline RB1 alterations; frequent losses on chromosome 16 and gains in chromosome 1q were also found. The MYC subtype displayed similarities with group 3 medulloblastoma; they also occurred at a younger age, and were characterised by MYC activation, chromosome 8p and 10q losses. No germline associations were identified in this group. In the core subtypes (group 1A, 1B and 2) alterations in genes of the miRNA processing pathway (namely DROSHA, DGCR8 and DICER1) were found in about 42% of cases, with all alterations being mutually exclusive. These genetic alterations had been previously reported [15,22]. The most frequent chromosomal alterations found in these subtypes were chromosome 8 gain and chromosome 16 loss for Group 1B and chromosome 14q loss for group 2.
Conclusion
PPT, although rare tumours, have variable prognosis and imply significant morbidity and mortality in young patients. Recent molecular data has been highlighting important differences between and within PPT histotypes. How to translate these new molecular data in a more precise diagnosis and better patient care is still a challenge.
For more information about Online Journal of Neurology and Brain Disorders archive page click on below link
For more information about lupine publishers page click on below link
#lupine publishers#lupine publishers group#lupine publishers LLC#online journal of neurology and brain disorders#ojnbd
1 note
·
View note
Last Seen Blogs
intimacy
intimacy
lordofthefeline
Don't Touch My Sketchbook
desire-in-the-present
it's Desire
dkavisen
avisen.nu
phantom-gifs
The Phantom